Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-Sirolimus in advanced solid tumors with moderate liver impairment
NCT05661461Phase 1Completed
- Sponsor
- Aadi Bioscience, Inc.
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in solid tumor, sponsored by Aadi Bioscience, Inc. Primary endpoints: Maximum Tolerated Dose at Day 22, Maximum concentration and 2 more. Started Nov 2022; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05661461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661461.